Short interest for Veru gives investors a sense of the degree to which investors are betting on the decline of Veru's stock. Short interest data is updated every two weeks.

Veru Stock (NASDAQ:VERU), Short Interest Report

Veru

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ADIL

AEYE

Alterity Therapeutics Limited - American Depositary Shares

ATHE

BHVN

BTCY

CENX

CMAX

Envoy Medical, Inc. - Class A Common Stock

COCH

DXYZ

EGIO

EXTR

HUBC

IMCC

INFA

KAVL

KUKE

LGVN

LOCL

MNDR

MRNS

NMRA

Nuveen California Dividend Advantage Municipal Fund 2

NXPL

ONVO

PROK

PSNY

QTTB

RARE

RENT

SNGX

SNPO

SPCB

SPWR

SRFM

SWVL

TCON

VERU

VIAO

WIRE

Shares of  Ultragenyx Pharmaceutical Inc.  (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Price Target

Analyst Ratings

CDNS

CHTR

CSCO

MASI

NTBL

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Cisco To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Monday

AGEN

ALLR

ANET

APLD

BENF

CISS

CPNG

EZGO

FRGE

GATO

GCTS

HRYU

INTZ

LOVE

LXEH

LYEL

MGRM

MOGU

MOTS

MRIN

NKLA

NRIX

PXMD

RLYB

SAVA

SBFM

SERA

Shares of  JPMorgan Chase &amp; Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings.

Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Veru Inc

VERUS INTL INC by Verus International, Inc.

Verus International Inc

VerusCoin

RCON

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

SOPA

VINO

Amazon.com Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) &#8220;Fallout&#8221; TV series has been a massive hit, drawing in 65 million viewers within just 16 days of its release, ranking as the second most-watched show since <a href="https://www.benzinga.com/topic/the-lord-of-the-rings">&#8220;The Lord of the Rings: The Rings of Power&#8221; in 2022. </a>
Notably, it&#8217;s Amazon&#8217;s top-performing series among adults aged 18-34, with a majority of its viewership coming from outside the U.S. The show was renewed for a second season shortly after its debut.
See Also: <a href="https://www.benzinga.com/general/gaming/24/04/38504776/next-gen-update-for-fallout-4-owners-excludes-ps-plus-collection-bethesda-confirms">Next-Gen Update For Fallout 4 Owners Excludes PS Plus Collection, Bethesda Confirms</a>
The executive producers, Lisa Joy and Jonathan Nolan, expressed their appreciation for the show&#8217;s success, thanking the cast and partners at Amazon and Bethesda. 
&#8220;Praise be to our insanely brilliant showrunners, Geneva and Graham, to our kick-ass cast, to Todd and James and all the legends at Bethesda, and to Jen, Vernon, and the amazing team at Amazon for their incredible support of this show,&#8221; Joy and Nolan <a href="https://variety.com/2024/tv/news/fallout-renewed-season-2-amazon-1235975879/">said </a>to Variety. &#8220;We can't wait to blow up the world all over again." 
The series&#8217; popularity has also sparked renewed interest in the Fallout video game franchise, with Fallout 76 attracting a whopping 1 million players in a single day. However, the release of Fallout 4&#8217;s next-gen upgrade was marred by technical issues, prompting Bethesda to promise fixes.
Read Next: <a href="https://www.benzinga.com/general/entertainment/24/04/38416256/amazons-fallout-series-sparks-record-gameplay-bethesda-reports-nearly-5-million-daily-playe">Amazon&#8217;s Fallout Series Sparks Record Gameplay; Bethesda Reports Nearly 5 Million Daily Players</a>
Photo: <a href="https://www.shutterstock.com/es/g/Popel+Arseniy">Popel Arseniy</a> on Shutterstock.

Entertainment

Gaming

AMZN

Amazon's 'Fallout' TV Series Blasts To 65M Viewers In 16 Days

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) has been on a downward trajectory recently, leaving many investors wondering what the <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38437196/this-famous-buy-bitcoin-sign-netted-an-intern-1m">future holds for the leading cryptocurrency.</a>
According to Markus Thielen&#8216;s <a href="https://mail.10xresearch.co/p/bitcoin-grinding-lower-10-catalysts-traders-watching?utm_source=mail.10xresearch.co&amp;utm_medium=newsletter&amp;utm_campaign=bitcoin-is-grinding-lower-10-catalysts-traders-are-watching">analysis</a>, the dynamics of Bitcoin trading have evolved significantly, necessitating a keen eye on specific events and developments.
<h1 class="wp-block-heading">Early Mining and Current Scarcity</h1>
Initially, Bitcoin offered substantial returns to early miners, with nearly 50% mined by 2012 and about 80% by 2017 when the prices were relatively low. 
Now, with 93.8% of Bitcoin mined, new market entrants are finding higher entry barriers and diminishing cycle returns. 
&#8220;Time in the market beats timing the market, but as Bitcoin matures, understanding and reacting to catalysts is vital for investment strategies,&#8221; Thielen notes.
<h1 class="wp-block-heading">Diminishing Returns and the Importance of Market Timing</h1>
From staggering 560x returns in 2013 to a modest 4-5x in the ongoing 2024 bull market, Bitcoin&#8217;s lucrative days of easy gains seem to be tapering off. 
The frequency of days yielding over 10% returns has also declined sharply, emphasizing the need for strategic market timing over a long-only investment approach.
<h1 class="wp-block-heading">Macro Factors and Regulatory Watch</h1>
Thielen highlights the influence of macroeconomic factors on Bitcoin. 
Notably, a halt in Bitcoin ETF inflows coincided with rising U.S. Consumer Price Index (CPI) and Producer Price Index (PPI) figures, underscoring the crypto&#8217;s sensitivity to inflation indicators. 
Additionally, regulatory developments remain a critical watchpoint. 
Despite a surge in Ethereum prices following a potential ETF listing, the approval odds remain slim. 
&#8220;Traders should mark May 23 and 24 on their calendars when the SEC decides on key ETF applications,&#8221; Thielen advises.
<h1 class="wp-block-heading">Federal Reserve Decisions and Economic Data</h1>
The upcoming Federal Reserve meeting on May 1 and subsequent economic releases including employment data and PPI figures are seen as potential catalysts. 
These events could indicate economic trends such as stagflation that significantly impact Bitcoin&#8217;s valuation.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38464921/michael-saylor-summarizes-why-microstrategy-is-superior-to-bitcoin-etfs">Michael Saylor Summarizes Why MicroStrategy Is Superior To Bitcoin ETFs</a>
<h1 class="wp-block-heading">Options Expiry and MicroStrategy's Influence</h1>
The recent options expiry on April 26 saw $9.4 billion in contracts mature, historically aiding in price stabilization. 
However, Thielen cautions about increased volatility until the next significant expiries due at the end of May and June.
MicroStrategy Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) strategic financial maneuvers, particularly under Michael Saylor's direction, have previously influenced Bitcoin's price. 
The <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38520610/whats-going-on-with-microstrategy-stock-tuesday">first-quarter earnings announcement on April 29</a> and anticipation of the potential early adoption of new FASB accounting guidelines could lead to significant price movements.
<h1 class="wp-block-heading">Index Inclusion and Market Saturation</h1>
Looking ahead, MicroStrategy&#8217;s potential inclusion in the S&amp;P 500 on June 1, dependent on its market cap and share availability, is another area drawing attention. 
&#8220;However, with the stock still overvalued, further capital raises might be on the horizon, though market saturation with MicroStrategy shares remains a concern,&#8221; Thielen adds.
As the landscape for digital assets continues to evolve, these catalysts provide critical waypoints for traders and investors. 
Such discussions will be further explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19, where industry leaders will converge to discuss the pathways and challenges in the <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38460707/stripe-makes-a-crypto-comeback-accepts-stablecoins-for-online-payments">burgeoning crypto economy.</a>
Read Next: <a href="EXCLUSIVE: Why The EigenLayer Airdrop Both Excites And Disappoints - Benzinga">EXCLUSIVE: Why The EigenLayer Airdrop Both Excites And Disappoints</a>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Sector ETFs

$BTC

MSTR

Bitcoin Grinds Lower: Catalysts Traders Will Watch For Their Next Moves

Ashford Hospitality Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHT#NYSE">AHT</a>) (&quot;Ashford Trust&quot; or the &quot;Company&quot;) today announced its preliminary expectations for net income attributable to common stockholders, Adjusted EBITDAre, and Adjusted FFO for the first quarter ended March 31, 2024.
The Company reported today a preliminary estimated range of net income attributable to common stockholders of approximately $66.4 million to $68.4 million or $0.59 to $0.61 per share, a preliminary estimated range of Adjusted EBITDAre of $58.5 million to $60.5 million, and a preliminary estimated range of Adjusted FFO available to common stockholders and OP unitholders of $(14.7) million to $(12.7) million for the first quarter ended March 31, 2024. Final results for the first quarter ended March 31, 2024 will be released on May 7, 2024, as previously announced.
We use certain non-GAAP measures, in addition to the required GAAP presentations, as we believe these measures improve the understanding of our operational results and make comparisons of operating results among peer real estate investment trusts more meaningful. Non-GAAP financial measures used in this press release, which should not be relied upon as a substitute for GAAP measures, are FFO, AFFO, EBITDA, EBITDAre and Adjusted EBITDAre. Please refer to our most recently filed Annual Report on Form 10-K for a more detailed description of how these non-GAAP measures are calculated. The reconciliations of non-GAAP measures to the closest GAAP measures are provided below and provide further details of our results for the periods being reported.
The following tables are reconciliations of the Company&#39;s preliminary estimated GAAP net income (loss) to the Company&#39;s preliminary estimated EBITDA, EBITDAre, Adjusted EBITDAre, FFO and Adjusted FFO:

Earnings

Guidance

Ashford Hospitality Trust Reports Preliminary Estimated Range Of Net Income ~$66.4M-$68.4M Or $0.59-$0.61 Per Share; EBITDAre Of $58.5M-$60.5M; Adj FFO $(14.7M)-$(12.7M) For Q1 Ended March 31, 2024. Final Results For Q1 Will Be Released On May 7, 2024

In a historic trading session on Tuesday, cannabis stocks soared following the <a href="https://www.benzinga.com/markets/cannabis/24/04/38530190/breaking-dea-reportedly-moves-to-reschedule-cannabis-stocks-rise-sharply-on-the-news">DEA&#39;s reported decision to reclassify marijuana</a> from Schedule I to Schedule III under the Controlled Substances Act.
This regulatory shift, which would align with a recommendation from the Department of Health and Human Services<a href="https://www.benzinga.com/markets/cannabis/24/04/38531355/cannabis-stocks-and-etfs-surge-as-dea-moves-to-reschedule-marijuana">&nbsp;sparked investor interest</a>
evidenced by gains in major cannabis stocks on the NASDAQ.
Canopy Growth Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NASDAQ">CGC</a>) led the gains, skyrocketing by 78.8% to close at $14.88 per share amid a trading frenzy that pushed the volume to 79.25 million shares.
Aurora Cannabis (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acb#NASDAQ">ACB</a>) wasn&#39;t far behind, climbing 46% to close at $9.23 per share with a volume of 37.921 million shares. Tilray Brands Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tlry#NASDAQ">TLRY</a>) also enjoyed an upswing, rising 39.5% to end the day at $2.47 per share with a volume of 147.306 million shares.
WM Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/maps#NASDAQ">MAPS</a>) saw a moderate increase of 1.44%, closing at $1.06 per share, with trading volume reaching 4.428 million shares.
The sudden uptick in these stocks highlights the market&#39;s optimistic reaction to the DEA&#39;s policy change, but when placed in the context of the year&#39;s performance, the perspective shifts slightly.
<h3>A Rocky Road</h3>
Aurora Cannabis, for example, experienced a robust recovery from its earlier slump in January, climbing 43.96% from its low in April before the most recent jump of 46%. Similarly, Canopy Growth Corporation managed a striking rally of 162.31% in March, despite a slight dip in April, culminating in an extraordinary single-day surge of 78.8%.
These fluctuations underscore a pattern of high volatility, suggesting that while the upsurges are significant, they are part of broader, unstable trading patterns that have characterized these stocks throughout the year.
Conversely, stocks like Tilray and WM Technology, Inc. have also shown significant swings, with Tilray rising 42.77% in March only to fall again in April&nbsp;and MAPS experiencing a decline of 21.43% after a strong gain.
These movements indicate that while the DEA&#39;s recent policy change has indeed injected a dose of optimism into the market, the broader year&#39;s perspective reveals fluctuating valuations.&nbsp;
Pro tip: Learn all about the future of the cannabis industry at the Benzinga Cannabis Capital Conference this October in Chicago. Hear directly from key industry players and policymakers. Get your tickets now by following&nbsp;<a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" rel="noopener noreferrer" target="_blank">this link</a>, and access a 20% discount using the code JAVI20.
<h3>Stock Performance In The Last Quarter</h3>
In the third quarter, Aurora <a href="https://www.benzinga.com/markets/cannabis/24/02/37011868/aurora-touts-41-yoy-increase-in-international-medical-cannabis-q3-revenue-expands-in-australia-v">reported</a> a modest rise in net revenue to CA$64.4 million ($68.7 million), up from CA$61.1 million in the same quarter last year, and growth in its medical marijuana segment, which saw a 16% increase to CA$45.1 million.
Tilray Brands showed a <a href="https://www.benzinga.com/markets/cannabis/24/04/38160302/cannabis-giant-tilray-reports-30-yoy-increase-in-q3-net-revenue-updates-fy-2024-guidance">stronger performance</a>&nbsp;with third-quarter net revenue jumping 30% year-over-year to $188.3 million with its adjusted gross profit improving by 17% to $51.6 million.
Conversely, Canopy Growth presented a <a href="https://www.benzinga.com/markets/cannabis/24/02/37034521/canopy-growth-reports-7-yoy-drop-in-q3-revenue-ceo-touts-new-era-for-company-as-it-seeks-us-list">mixed financial picture</a>, noting an 81% increase in its &ldquo;rest-of-world&rdquo; cannabis revenue, which reached CA$10.5 million. Yet&nbsp;its core Canadian cannabis segment experienced a decline, with net revenue falling from CA$46.6 million in the prior year&#39;s quarter&nbsp;to CA$39 million.&nbsp;
<h3>What Happens Next?</h3>
As the DEA proposes reclassifying cannabis from Schedule I to Schedule III, the Marijuana Policy Project <a href="https://www.benzinga.com/markets/cannabis/24/04/38531267/marijuana-policy-project-reacts-with-scepticism-to-deas-proposal-to-reschedule-cannabis">noted </a>the limited impact this change has on the criminalization of cannabis users under state laws and advocates for more robust state-level initiatives for comprehensive cannabis legalization and fair medical laws.
The U.S. Cannabis Council, through its executive director Edward Conklin, <a href="https://www.benzinga.com/markets/cannabis/24/04/38531182/us-cannabis-council-call-dea-historic-decision-to-reclassify-cannabis-a-tectonic-shift">described</a> the DEA&#39;s decision as a &quot;tectonic shift&quot; in drug policy, emphasizing the economic and social benefits expected from moving cannabis to Schedule III, including potentially ending the restrictive 280e&nbsp;tax penalty.
In a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38226873/analyst-reacts-to-fda-commish-comments-medical-and-recreational-cannabis-could-have">recent report</a>, senior analyst Pablo Zuanic suggested the rescheduling&nbsp;of cannabis could focus primarily on medical cannabis, which could allow for more controlled and supported medical use under federal guidelines.
This would enable better research, development&nbsp;and medical application of cannabis, enhancing its legitimacy and accessibility as a therapeutic substance.
<h3>Who Wins With Rescheduling?</h3>
The rescheduling of cannabis carries implications for <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/08/33482140/rescheduling-cannabis-what-are-the-implications-for-msos-tax-rule-280e-fda-and-phar">various stakeholders within the industry</a>, including multistate operators, pharmaceutical companies&nbsp;and federal regulatory bodies like the FDA.
Removing <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/08/33482521/curaleaf-and-trulieve-lead-the-pack-in-tax-payments-a-look-at-16-cannabis-msos-liab">Tax Rule 280E </a>could increase profitability for U.S. cannabis businesses by lowering their effective tax rates, which have been notably high. This advantage is balanced by the introduction of potential FDA oversight and the entry of pharmaceutical companies into the market.
This transition could render cannabis federally legal under certain schedules, increasing regulatory requirements and altering the competitive landscape by enabling pharmaceutical entities to potentially dominate, especially in the medical cannabis segment.
The reduction of the 280E tax burden would provide financial relief but also bring the risk of enhanced regulation and operational challenges. Zuanic also points out that MSOs might see <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/08/34153665/cannabis-tax-changes-could-trigger-504-cash-flow-leap-which-industry-players-will-b">improvements in cash flow management</a> and tax reductions.&nbsp;
Photo: AI-Generated Image.&nbsp;

Analyst Color

Cannabis

Government

Regulations

Politics

Legal

MAPS

TLRY

Cannabis Stocks React To DEA Rescheduling: Canopy & Aurora Surge, Tilray, WM Tech Hold Steady

The battle between Donald Trump and Joe Biden for the White House is nearing the six-month mark for voters to decide which candidate will win the<a href="https://www.benzinga.com/topic/2024-election"> 2024 election on Nov. 5, 2024.</a>
A new poll shows how voters in key swing states would vote today.
What Happened: Many<a href="https://www.benzinga.com/topic/election-poll"> election polls </a>point to a close race between Biden and Trump in the 2024 election, an event that could be a rematch of the 2020 presidential election won by Biden.
A new Emerson College poll shows how voters in key swing states would vote in a head-to-head matchup of Trump and Biden and also how they would vote when the two candidates face off against key third-party candidate Robert F. Kennedy Jr.
Here are the results for the head-to-head <a href="https://emersoncollegepolling.com/trump-holds-edge-over-biden-in-seven-key-swing-state-polls/">poll</a>:
Arizona: 44% Biden, 48% Trump, 8% Undecided
Georgia: 44% Biden, 47% Trump, 9% Undecided
Michigan: 44% Biden, 45% Trump, 11% Undecided
Nevada: 44% Biden, 45% Trump, 11% Undecided
North Carolina: 42% Biden, 47% Trump, 10% Undecided
Pennsylvania: 45% Biden, 47% Trump, 8% Undecided
Wisconsin: 45% Biden, 47% Trump, 8% Undecided
The poll shows Trump winning all seven states in the head-to-head matchup against Biden. Trump's lead is only one point in several states.
"The share of undecided voters has reduced and Biden gained ground in Georgia and Nevada, narrowing the gap, while Trump has maintained a slight edge on Biden in Pennsylvania and Wisconsin," Emerson College Polling executive director Spencer Kimball said.
Here are the results of the poll when Robert F. Kennedy and other candidates are considered. The remaining percentage for each state went to other or undecided.
Arizona: 40% Biden, 44% Trump, 9% Kennedy Jr.
Georgia: 39% Biden, 45% Trump, 5% Kennedy Jr.
Michigan: 42% Biden, 43% Trump, 5% Kennedy Jr.
Nevada: 37% Biden, 42% Trump, 8% Kennedy Jr.
North Carolina: 37% Biden, 46% Trump, 6% Kennedy Jr.
Pennsylvania: 41% Biden, 45% Trump, 6% Kennedy Jr.
Wisconsin: 40% Biden, 45% Trump, 6% Kennedy Jr.
When third-party candidates are included for voters, Biden loses more support than Trump in five states. Two states (Arizona, Michigan) see both Biden and Trump lose the same amount of support.
Related Link: <a href="https://www.benzinga.com/general/politics/24/04/38348604/biden-vs-trump-new-poll-shows-tie-in-2024-election-race-one-candidate-gains-among-independent-vo">Biden Vs. Trump: New Poll Shows Tie In 2024 Election Race, One Candidate Gains Among Independent Voters</a>
Why It's Important: The poll results show Trump with a lead in all states in head-to-head and with other candidates to choose from.
The poll also found that Independent voters favored Trump over Biden in five of the swing states with Biden winning in Georgia and Wisconsin. Biden also led Trump in the states of Michigan, Pennsylvania and Wisconsin among voters who are members of labor unions.
The other bad news for Biden was the poll asking voters about the <a href="https://www.benzinga.com/general/politics/24/04/38326553/trump-hush-money-trial-has-12-jurors-here-are-the-7-men-5-women-to-decide-former-presidents-fate">criminal case against Trump</a> alleging hush money payments. The poll found that voters in six of the seven states said they were more likely to support Trump if he's found guilty in the case versus the number of voters who said they were less likely to support Trump.
The <a href="https://www.benzinga.com/general/politics/24/03/37884006/trump-vs-biden-key-swing-states-arizona-nevada-michigan-wisconsin-show-close-races-heres-the-rol" target="_blank" rel="noreferrer noopener">seven swing states </a>together represent 93 electoral votes in the 2024 election. Six of the seven swing states were won by Biden in the 2020 election, with Trump winning North Carolina. Five of the seven swing states won by Biden in 2020 flipped from Trump&#8217;s win in 2016, including Arizona, Michigan and Wisconsin.
While the 2024 election is months away, recent polls of voters in swing states have not shown favorable results for Biden, which could be worrisome for his campaign.
Read Next: <a href="https://www.benzinga.com/general/politics/24/04/38523639/judge-threatens-trump-with-incarceration-fines-him-for-violating-gag-order-jail-may-be-a-necessa">Judge Threatens Trump With Incarceration, Fines Him For Violating Gag Order: &#8216;Jail May Be A Necessary Punishment&#8217;</a>
Photos: Shutterstock

Trump Vs. Biden: Former President Holds Lead In All 7 Swing States, Which Candidate Does Robert F. Kennedy Jr. Hurt More?

Huron Consulting Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURN#NASDAQ">HURN</a>) reported quarterly earnings of $1.23 per share which beat the analyst consensus estimate of $0.89 by 38.2 percent. This is a 41.38 percent increase over earnings of $0.87 per share from the same period last year. The company reported quarterly sales of $355.961 million which beat the analyst consensus estimate of $351.014 million by 1.41 percent. This is a 11.97 percent increase over sales of $317.895 million the same period last year.

Earnings Beats

HURN

Huron Consulting Gr Q1 2024 Adj EPS $1.23 Beats $0.89 Estimate, Sales $355.961M Beat $351.014M Estimate

Investors who bought leading cryptocurrency Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) years ago likely enjoyed a strong 2024 that saw the approval of Bitcoin ETFs and new all-time highs reached on several occasions <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37498047/exclusive-bitcoin-hits-new-all-time-high-heres-when-benzinga-readers-think-100k-milestone-#:~:text=While%20the%20all%2Dtime%20high,52%2Dweek%20high%20of%20%2468%2C789.63.">in March.</a>
A YouTuber begged people to put $1 into Bitcoin in a video shared on May 9, 2013. Here's a look back at the video and how much viewers could have made following his advice.
What Happened: YouTuber Davinci Jeremie launched several videos about Bitcoin prior to 2013, including those calling for viewers to<a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38041549/trader-who-urged-everyone-to-buy-1-of-bitcoin-in-2013-now-advocates-for-dogecoin-killer-sh"> buy $1 in Bitcoin.</a>
His most famous video was one from May 9, 2013, titled "Bitcoin update – just buy $1 worth of bitcoin please!"
In the <a href="https://www.youtube.com/watch?v=Cw29h7LhEuE">video</a>, Jeremie told viewers Bitcoin "is more than just a payment system." The YouTuber praised Bitcoin creator Satoshi Nakamoto in the video and said the cryptocurrency could remain free and open and accomplish many things in the future.
"It is a freedom provider for the rest of humanity," Jeremie said.
Jeremie recognized many viewers were skeptical of Bitcoin, but he suggested investing a small amount of money and putting it into Bitcoin, then placing the investment aside for years.
"I suggest you take one fricking dollar, one dollar, buy some Bitcoins."
The YouTuber said it's just a dollar so if the investment goes to zero, you're not out much.
"It's just a dollar, get some Bitcoins."
Jeremie said he knew most viewers wouldn't take his advice.
"You're going to be thanking me."
Fast forward to 2024 and listening to Jeremie's advice could have netted huge returns for anyone who listened to his YouTube video.
Bitcoin traded between $109.60 and $115.78 on May 9, 2013, the date the video aired on YouTube, according to data from <a href="https://www.statmuse.com/money/ask/bitcoin-price-may-2013">Statmuse</a>. 
Investing $1 at the time could have purchased 0.0086 Bitcoin based on the day's high price. Today that $1 investment would be worth $516.26 based on a price of $60,029.90 for Bitcoin at the time of writing.
This marks an incredible return of 51,526% over the past 11 years.
Investors who felt more risky and invested $1,000 could have turned their investment into $518,484.25 over the past 11 years.
Related Link: <a href="https://www.benzinga.com/markets/cryptocurrency/24/02/37381457/if-you-bought-1-worth-of-bitcoin-at-launch-heres-how-much-youd-have-today">If You Bought $1 Worth Of Bitcoin At Launch, Here&#8217;s How Much You&#8217;d Have Today</a>
Why It's Important: While it may be easy to look back at Jeremie's advice today and celebrate it at the time cryptocurrency was still considered a risky trade to many.
The key to Jeremie's video was the relative small investment amount he proposed. In the video description he mentioned buying Bitcoin "for the price of a lotto ticket" and holding it for 10 years.
The hypothetical investment illustrates how a small investment can grow over time. The small amount also shows the risk/reward profile illustrated by Jeremie who told viewers that if Bitcoin went to $0 they were only out the $1 they put into the cryptocurrency.
Jeremie has grown his following on YouTube to 519,000 <a href="https://www.youtube.com/channel/UCP0g6ygQkYjmog801YnNqtQ">subscribers </a>thanks to his previous call on Bitcoin. The content creator also has over 600,000 followers on <a href="https://www.instagram.com/davincij15/?hl=en">Instagram</a>.
Benzinga recently wrote that Jeremie has been advocating for Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) when asked by followers about the meme coin.
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/01/36462666/if-you-invested-1-000-in-bitcoin-at-the-last-bitcoin-halving-heres-how-much-youd-have-toda">If You Invested $1,000 In Bitcoin At The Last Bitcoin Halving, Here&#8217;s How Much You&#8217;d Have Today</a>
Photo: <a href="https://www.shutterstock.com/g/Mc_Cloud">Mc_Cloud</a> via Shutterstock

Education

$SHIB

If You Invested $1 In Bitcoin When YouTuber Said 'One Dollar, Buy Some Bitcoins,' Here's How Much You'd Have Today

OPGN

UPDATE: OpGen deal was announced Monday.

Euro Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLWT#NASDAQ">CLWT</a>) reported quarterly earnings of $0.24 per share. This is a 380 percent increase over earnings of $0.05 per share from the same period last year. The company reported $17.94 million in sales this quarter. This is a 20.01 percent increase over sales of $14.95 million the same period last year.

CLWT

Euro Tech Hldgs FY EPS $0.24 Up From $0.05 YoY, Sales $17.94M Up From $14.95M YoY

WIIM

Viant Technology shares are trading higher after the company announced better-than-expected Q1 results and authorized a repurchase program.

Asset Sales

PG&E Comments In Emailed Statement, Sees Deal With KKR Cutting Rates By $100M+ Over Next 20 Years; Would Remain Majority Owner Of Pacific Generation

LMND

Lemonade shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY24 revenue guidance above estimates.

POAI

Predictive Oncology shares are trading higher after the company announced a collaboration with FluGen for an intranasal flu vaccine.

ROOT

Root shares are trading higher after the company reported better-than-expected Q1 financial results.

Caesars Entertainment shares are trading lower following a Q1 revenue miss.

POWL

Powell Industries shares are trading higher after the company reported better-than-expected Q2 financial results.

10x Genomics shares are trading lower following worse-than-expected Q1 results.

Veru Q1 2024 Earnings Preview

Veru reports Q1 results

Veru Inc. (VERU) Q1 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
<a href="https://investorplace.com/stock-types/penny-stocks/">Penny stocks</a> will always provide us with investment opportunities in the event that we do not have a completely high buying power and do not want to buy fractional shares. In the large ecosystem of companies that make life in the financial markets, we can always identify good investment opportunities that allow us to add value to our portfolio and our wealth. Here are three best penny stocks to buy, let&rsquo;s take a quick look.



<h2>Atyr (LIFE)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3-300x169.jpg" alt="Photo of test tubes and droplet with purple and reddish-orange sunset visual effect, representing biotech"><div>Source: shutterstock.com/Romix Image</div></div>


We begin our list of penny stocks with great potential with Atyr Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/life-stock-quote/">LIFE</a>), which is in charge of creating innovative treatments, focusing on efzofitimod, which is a unique biologic that is designed to treat inflammation without the need to weaken the immune system.



This treatment is undoubtedly a great hope for patients with severe diseases such as systemic sclerosis.



<a href="https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-third-quarter-2023-results-and-provides">Financially</a> they have made remarkable achievements. They achieved a solid cash and investment position of approximately $105.6 million.



Thanks to this excellent financial strength, they have been able to continue their research to achieve major clinical milestones, such as the filing of a biologic license application for efzofitimod in pulmonary sarcoidosis.



Their major achievements also include the <a href="https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-dosing-first-patient-phase-2-efzo">initiation</a> of the Phase 2 EFZO-CONNECT study, which is focused on patients with interstitial lung disease, which is related to systemic sclerosis.



This study has presented a very crucial advance towards the validation of the treatment as an effective and completely safe therapeutic option.



But they are not stopping there, as they have demonstrated that they are fully committed to their goals and to sharing their breakthroughs with the scientific community. They have <a href="https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-present-posters-highlighting-importance-neuropilin-2">presented</a> two posters at the Keystone Symposia.



<h2>Palatin (PTN)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1726134715-300x169.png" alt="Biochemical/biotech research scientist team working with microscope"><div>Source: Mongkolchon Akesin / Shutterstock.com</div></div>


We continue with Palatin Technologies (NYSE:<a href="https://investorplace.com/stock-quotes/ptn-stock-quote/">PTN</a>), which operates in the biopharmaceutical world. It has a flagship product called Vyleesi, which is intended to help women with HSDD. This product has experienced a huge increase in demand, which is reflected in revenues as well.



Talking about their <a href="https://palatin.com/press_releases/palatin-reports-first-quarter-fiscal-year-2024-financial-results-and-provides-corporate-update/">finances</a>, this company is very stable and has a steady growth.



As mentioned earlier, they have reported a significant increase in Vyleesi&rsquo;s gross sales and net income, combined with a decrease in operating expenses.



Part of their latest <a href="https://palatin.com/press_releases/palatin-announces-database-lock-for-pl9643-melody-1-pivotal-phase-3-clinical-trial-in-patients-with-dry-eye-disease-ded/">development</a>, the Phase 3 MELODY-1 trial, which is for dry eye disease (DED), has reached a very significant milestone with the closure of the database.



Positive results from this trial are likely to lead the way for further advances in the company&rsquo;s pipeline.



Not only do they have that achievement, but they have also strategically entered into an <a href="https://palatin.com/press_releases/palatin-completes-sale-of-vyleesi-to-cosette-pharmaceuticals-for-up-to-171-million/">agreement</a> to sell Vyleesi to Cosette Pharmaceuticals for approximately $171 million.



<h2>Veru (VERU)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1726134715-300x169.png" alt="Biochemical/biotech research scientist team working with microscope"><div>Source: Mongkolchon Akesin / Shutterstock.com</div></div>


And we round out this list with great potential with Veru (NASDAQ:<a href="https://investorplace.com/stock-quotes/veru-stock-quote/">VERU</a>), which is a company that also operates in the biotechnology sector and specializes in the development of innovative treatments to address high-quality weight loss, cancer, and ARDS.



As part of its major achievements it has received FDA <a href="https://ir.verupharma.com/news-events/press-releases/detail/196/veru-announces-fda-clearance-of-ind-application-to-initiate">approval</a> to run a Phase 2b clinical trial on enobosarm, which is an androgen receptor modulator with great potential. This drug is aimed at preserving muscle mass and physical function.



This company has a great focus and dedication to improving the quality of life of patients, and is highlighted all the more by the concern shown by the CDC, who has <a href="https://ir.verupharma.com/news-events/press-releases/detail/193/veru-submits-ind-application-to-fda-for-the-development-of">reported</a> on the high percentage of older adults in the United States suffering from obesity and sarcopenia.



All of their dedication, focus and results are evident in their <a href="https://ir.verupharma.com/news-events/press-releases/detail/197/veru-reports-fiscal-2024-first-quarter-financial-highlights">financial</a> health, where they have had a considerable increase in cash and cash equivalents.







As of this writing, Gabriel Osorio-Mazzilli did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines&nbsp;(no position)
<div>Gabriel Osorio is a former Goldman Sachs and Citigroup employee. He possesses discipline in bottom-up value investing and volatility-based long/short equities trading.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT766413">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/02/the-3-best-penny-stocks-to-buy-in-february-2024/">The 3 Best Penny Stocks to Buy in February 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

The 3 Best Penny Stocks to Buy in February 2024

Veru gets Nasdaq notice related to delayed quarterly report on form 10-Q

Veru Inc (VERU) stock is higher by 22.81% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator. Veru Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on VERU!See Full VERU ReportWhat is Stock Sentiment?Sentiment uses short term technic

Do Traders Think Veru Inc (VERU) Can Keep Climbing Thursday?

NKTR, VERU and EGIO among mid-day movers

Veru, Theravance Biopharma, Adial Pharmaceuticals among healthcare movers

Veru, EyePoint Pharmaceuticals, SINTX Technologies among healthcare movers

LI, VERU and MRIN among pre-market losers

AGBA

ALPN

ALRN

APVO

BATL

BPTH

BSGM

CADL

CURI

DCFC

ELYM

ENLV

ENTX

EYPT

HYMC

INVO

LIFE

LIFW

MLEC

NFLX

NKTR

RCEL

SINT

SMSI

TBPH

THCH

VVPR

Press Releases

Veru Reports Fiscal 2024 First Quarter Financial Highlights

Management

Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss

Healthcare Innovations and Collaborations Fuel Industry Expansion Stocks Under $1 Look Now! OCGN, VTAK, RSCI, VERU, AGEN

Biotech With Potential: Coeptis Therapeutics (COEP) And 3 Underrated Gems

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Veru Stock (NASDAQ:VERU), Short Interest Report

People Also Watch